For Petrovax, 2019 was marked by a significant growth in revenue that went up 22.1 % year-on-year to reach 9.8 billion RUB. Longidaza® (+75%, Grippol® plus (+9%), and Polyoxidonium® (+8%) were among the medicinal products with the highest sales growth rates in rubles.
In line with its sustained growth strategy, the company has significantly increased sales in Russia and grown its market share abroad. As of 2019, exports accounted for 12.3 % of Petrovax’s total sales, with export supplies exceeding 1.2 billion RUB. Drug exports grew by 27.7 % in value terms. The company’s geographic footprint embraces 12 countries, with major export flows coming to the CIS, Slovakia, and Iran.
Before the 2019-2020 epidemic season, the company supplied 8 million shots of influenza prevention vaccine Grippol® plus for the Russian commercial market and for exports to Belarus, Kazakhstan, Kyrgyzstan, and Uzbekistan, including for the national immunization programs.
In 2019, the company successfully launched Velson® (melatotin). The product helps one fall asleep as soon as possible and improves quality of sleep. In July 2019, Petrovax started shipping Velson® across Russia. The company plans exporting the product to the CIS...
Full text at GMPnews.Net